Lung Cancer

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

The development of more effective treatments — including personalized therapies — have dramatically improved outcomes for children and adolescents with cancer, according to American Association for Cancer Research’s Cancer Progress Report.

Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer.

Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.

Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers persist, according to survey results.

Patients with central airway obstruction are often treated by multiple clinicians from different specialties, leading to varied management of the patients, according to a press release.

Alternative lung cancer screening criteria may identify more individuals, who would benefit from screening compared with current guidelines, study results showed.

Current evidence does not support lung cancer screening for never-smokers or former light smokers with a family history of lung cancer, according to a commentary in Journal of Thoracic Oncology.

Exposure of certain cardiac structures to radiation during treatment of surgically inoperable or unresectable non-small cell lung cancer was associated with increased arrhythmia risk, researchers reported.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.